Since the actions of androgens and androgen receptor (AR) are among the drivers of prostate cancer [2], one of the therapeutical approaches to treat prostate cancer is androgen deprivation therapy (ADT) and the downregulation of AR signaling, which is accomplished by various strategies [3]. This evidence concerns the gene AR and prostate carcinoma.